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Abstract  
Background: Human visceral leishmaniasis (VL) vaccines are currently under development 
and there is a need to understand their potential impact on population wide VL incidence. 
Methodology / Principal Findings: We implement four characteristics from different human 
VL vaccine candidates into two published VL transmission model variants to estimate the 
potential impact of these vaccine characteristics on population-wide anthroponotic VL 
incidence on the Indian subcontinent (ISC). The vaccines that are simulated in this study 1) 
reduce the infectiousness of infected individuals towards sand flies, 2) reduce risk of 
developing symptoms after infection, 3) reduce the risk of developing post-kala-azar dermal 
leishmaniasis (PKDL), or 4) lead to the development of transient immunity. We also compare 
and combine a vaccine strategy with current interventions to identify their potential role in 
elimination of VL as public health problem. We show that the first two simulated vaccine 
characteristics can greatly reduce VL incidence. For these vaccines, an approximate 60% 
vaccine efficacy would lead to achieving the ISC elimination target (<1 VL case per 10,000 
population per year) within 10 years’ time in a moderately endemic setting when vaccinating 
100% of the population. Vaccinating VL cases to prevent the development of PKDL is a 
promising tool to sustain the low incidence elimination target after regular interventions are 
halted. Vaccines triggering the development of transient immunity protecting against 
infection lead to the biggest reduction in VL incidence, but booster doses are required to 
achieve perduring impact. 
Conclusions / Significance: Even though vaccines are not yet available for implementation, 
their development should be pursued as their potential impact on transmission can be 
substantial, both in decreasing incidence at the population level as well as in sustaining the 
ISC elimination target when other interventions are halted.  
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Author summary 
Vaccines for human visceral leishmaniasis (VL) are currently under development. In this 
study, we simulate VL transmission dynamics using mathematical models to explore the 
potential impact of vaccines on population-wide incidence. We show that some vaccines have 
high potential to reduce VL incidence, namely those that reduce the infectiousness of infected 
individuals to sand flies and those that reduce the chance of developing symptoms once 
infected. The effect of vaccines that lead to protection from infection is potentially the 
greatest, but depending on the duration of immunity, individuals would require booster doses 
to guarantee lifelong impact. Vaccines that prevent the development of post-kala-azar dermal 
leishmaniasis are a promising tool to sustain low VL incidence and prevent recrudescence of 
infection when regular interventions are halted. Our results strongly support the continued 
development of VL vaccines, as their potential impact on population incidence can be 
substantial. 
 
Introduction 
Visceral leishmaniasis (VL), also known as kala-azar, is a vector-borne neglected tropical 
disease. Infection occurs after successful transmission of the Leishmania protozoa through 
the bite of an infected female sand fly [1]. Most infected humans remain asymptomatic, and 
only a small proportion of about 1—10% develop clinical symptoms, resulting in death when 
left untreated [2,3]. Between 5% and 20% of treated VL cases develop a long-lasting skin 
condition known as post-kala-azar dermal leishmaniasis (PKDL). Recent studies have 
identified that individuals with PKDL are equally infectious towards sand flies as VL cases, 
making them an important reservoir of infection [4,5]. However, the contribution of 
asymptomatic individuals to transmission has not yet been defined [4,6]. After infection, a 
period of immunity follows, of which the duration remains debated.  
Currently around 33,000—66,000 individuals develop symptomatic VL each year, mainly on 
the Indian subcontinent (ISC), Eastern Africa, the Mediterranean region, and Brazil, affecting 
the poorest of the poor [7,8] . The World Health Organization (WHO) and affected countries 
target for ‘elimination of VL as a public health problem by 2020’ on the ISC, where VL is 
considered to be solely anthroponotic. This target is defined as less than 1 VL case per 
10,000 individuals at (sub)district level per year. In the rest of the world (e.g Africa, Europe, 
Brazil), where VL can also be zoonotic with the main reservoir of infection in dogs, the target 
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is 100% detection and treatment of symptomatic cases [9]. Current strategies consist of 
diagnosis and treatment of VL cases, and vector control.  
 
Vaccines already play an important role in the control of canine leishmaniasis, at the 
individual level they reduce the development of symptoms, reduce the parasite load in the 
blood, and reduce the risk of death [10,11]. These vaccines have also proven to be effective at 
the population level by reducing Leishmania transmission, resulting in lower incidence in 
both dogs and humans [12,13]. The development of human VL vaccines has been on-going 
for decades and there are different vaccine candidates currently in trial, but none are yet 
available for implementation [14,15]. The promising results from experimental human VL 
vaccine trials, and by the practice of “leishmanization”, in which a healthy individual is 
artificially exposed to tissue scrapings derived from a cutaneous leishmaniasis patient, 
leading to disease prevention [6,14,16–18], provide strong evidence for the scientific 
feasibility of an effective vaccine against human VL. Would an effective vaccine become 
available, it has been estimated to be cost-effective when used at large scale and in addition 
to ongoing diagnosis and treatment, without even accounting for its impact on transmission 
[17]. 
 
Mathematical transmission models are useful tools to gain insight into the effect of current 
and future interventions on VL incidence and the underlying transmission dynamics. 
Previous modelling studies that focused on VL transmission on the ISC presented two model 
variants; one in which only VL and PKDL cases contribute to transmission, and another in 
which also asymptomatic individuals contribute to transmission (~1% relative to VL cases). 
The models estimated that in most situations on the ISC, the target is likely to be met with 
current strategies but in high endemic settings and at a lower geographical scale, additional 
efforts are required. They also highlighted the risk of recrudescence of infection after 
achieving the low incidence target, when halting interventions. This is mainly due to 
individuals with PKDL and/or asymptomatic infection. Therefore, the studies emphasized the 
need for further research on the potential impact of preventive VL and PKDL strategies as a 
tool in reaching and sustaining VL elimination on the ISC [19,20]. Other studies stressed that 
100% detection and treatment of cases in the rest of the world remains challenging and that 
prevention could be much more effective than case detection and treatment [21]. 
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In this study, we implement multiple characteristics of potential human VL vaccines using 
two variants of a deterministic VL transmission model [19] to estimate the potential impact 
of these vaccine characteristics on VL incidence and transmission dynamics during and after 
the achievement of the current elimination target. The vaccines that are simulated in this 
study 1) reduce the infectiousness of infected individuals towards the sand fly, 2) reduce the 
risk of developing symptoms after infection, 3) reduce the risk of development of PKDL, or 
4) lead to the development of transient immunity to infection [22–24]. We also compare and 
combine vaccine characteristics with current interventions to identify which vaccines could 
be most impactful in fighting this neglected tropical disease.  
 
 
Methods 
Overview of VL vaccine candidates and characteristics 
Currently there are various VL vaccine candidates under study [25]: LEISH-F3+GLA-SE 
[26,27], and ChAd63-KH (ISRCTN07766359) [28] are currently in clinical development; 
Ad5-A2/rA2 Prime / Boost [29], genetically modified live attenuated whole parasites 
[23,24,30], and a LmCen-/- vaccine [31] are being developed for the clinic [32]. 
 
These vaccines have different physical and immunological properties, and could be used in 
either prophylactic or therapeutic settings, but their impact following infected sand fly bite in 
humans has yet to be evaluated. Table 1 summarizes different potential vaccine outcome 
measures (herein called characteristics) that were selected for simulation in this study. 
Vaccine characteristic 1 is separated into 1a) asymptomatic individuals and 1b) all infected 
individuals, because it is suggested that only individuals with asymptomatic infection may be 
affected by the vaccine and that once an individual develops symptoms there are no 
differences in infectiveness (1a). However, since this is not yet well established, we also 
include the option where all infected individuals become less infective, as a result of the 
vaccine (1b).  
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Table 1. Human VL vaccine characteristics. 
Number Vaccine characteristic 
1a Reduced infectivity of asymptomatic individuals  
1b Reduced infectivity of all infected individuals 
2 Reduced risk of developing symptoms 
3 Reduced risk of developing PKDL 
4 Development of transient immunity protecting against infection 
 
 
Transmission models and simulation of existing interventions 
Fig 1 illustrates the basic structure of the VL transmission model, which is a deterministic 
age-structured model. There are two model variants, that only differ based on assumptions 
about where the main reservoir of infection lies; namely, solely in symptomatic individuals 
(VL and PKDL), or mainly in asymptomatic individuals [19,33,34]. The models were 
parameterized with age-structured data on approximately 21,000 individuals included in the 
KalaNet bednet trial in India and Nepal [35] and have undergone geographical cross-
validation against data on >5000 VL cases from 8 endemic districts in Bihar collected by 
CARE India [36] (see [34] for full model descriptions and sensitivity analyses). Recent 
outcomes from xenodiagnosis studies have been incorporated, indicating that those with 
PKDL are on average nearly as infectious as those with VL (0.9:1.0) [4,5]. 
 
Interventions of which the effects have previously been modelled are vector control through 
indoor-residual spraying of insecticide (IRS) and active case detection (ACD). The 
guidelines, as developed by WHO, recommend a 5-year attack phase (intense IRS and ACD) 
followed by 5 years of consolidation phase (IRS and intense ACD). In our models, IRS leads 
to a decrease in sand fly density and ACD shortens the duration of the symptomatic untreated 
stage.  
 
Implementation and simulation of four vaccine characteristics 
Vaccine characteristic 1 is simulated by a reduction in infectiousness of infectious states 
towards the sand fly. For vaccine characteristics 2 and 3, the respective flow towards clinical 
VL and PKDL is reduced. With vaccine characteristic 4, we selected 100% development of 
transient immunity after having received the vaccine and experimented with vaccinating 
100% and 50% of the population. The duration of immunity after vaccination is assumed to 
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be to 2 years, which is similar to the assumed duration of immunity after natural infection in 
our model of which sensitivity analyses are presented in previous work [34]. 
 
For the simulations of vaccine characteristics, we assume that they apply to everyone 
involved, i.e. all ages and sexes. No specific target populations are simulated, besides for 
vaccine characteristic 3, which is only administered to those that have developed VL. For 
vaccine characteristics 1-3, we assume an arbitrary 50% reduction of the infectiousness as 
well as a 50% reduction of the proportions of individuals that develop VL and PKDL, all in 
combination with a 100% vaccination coverage. We also calculate the percentage of vaccine 
effectiveness required to achieve the VL elimination target incidence of 1/10,000/year within 
10 years of starting the intervention, which could aid in defining a vaccine target product 
profile (TPP). We assume that the vaccine characteristics are in place constantly from the 
start of the intervention, except for vaccine characteristic 4, where we experiment with 
simulating a single vaccination round and repeated yearly vaccination rounds. For all four 
vaccine characteristics, we separately simulate and compare their impact on VL incidence 
over time, even though it is likely that one vaccine will possess multiple characteristics. The 
cumulative effects of some vaccine characteristics are simulated indirectly, as reducing the 
development of VL will lead to a decrease in the overall development of PKDL. Previous 
work has shown that when current existing interventions have led to the 1/10,000/year target, 
there are many susceptible individuals and the infection pressure comes mainly from PKDL 
cases (when assuming the infection pressure originates from symptomatic individuals only) 
[19]. To address this, we also combine vaccine characteristic 3, vaccination of VL cases to 
prevent the development of PKDL, with the current interventions recommended by WHO.  
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Fig 1. Schematic presentation of the model variant in which asymptomatic individuals contribute to 
transmission, with numbers related to different types of vaccine characteristics that are 
implemented in the models. In the alternative model variant, asymptomatic individuals are assumed not 
to be infectious towards to sand fly, with infection pressure only coming from symptomatic individuals 
with VL (with and without treatment) and PKDL. Once a susceptible individual is infected by an 
infectious sand fly, they become early asymptomatic for an average duration of about 200 days, which is 
followed by the late asymptomatic stage (average duration of 69 days). The average infectivity of both 
asymptomatic stages together is 0 in the model in which they do not contribute and ~1.5% relative to VL 
in the model in which they contribute to transmission. 1.4% of late asymptomatic individuals develops VL, 
and without active case detection, the duration between onset of symptoms and start of treatment lasts on 
average 40 days, followed by 1-day treatment 1 and potentially 28-day treatment 2 or death if left 
untreated. The average duration of the putatively recovered stage is 21 months and 5% of these individuals 
develop PKDL which lasts 5 years on average. The infectivity of PKDL is 90%, relative to VL. The rest 
recovers to the early recovered stage (average duration of 74 days), followed by the late recovered stage 
(average duration of 2 years), which can be interpreted as the duration of immunity. The numbers in the 
red boxes relate to the numbers in the first column of Table 1 and represent the following vaccine 
characteristics; 1a) early and late asymptomatic individuals become half as infectious, 1b) all infection 
states become half as infectious, 2) vaccinated individuals are 50% less likely to develop symptoms, 3) 
vaccinated individuals are 50% less likely to develop PKDL, and 4) vaccinated individuals develop 
transient immunity against infection.  
 
4
2
3
1a
1b
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Results 
The impact of each of the four vaccine characteristics on VL incidence is illustrated in Fig 2. 
A vaccine that reduces infectivity of asymptomatic individuals by 50% (1a) leads to the 
elimination target being achieved in about 11 years. When all infected individuals have a 
reduced infectiousness of 50% (1b), the decline is steeper, achieving elimination in around 4 
years if asymptomatics are the main reservoir of infection and 11 years when infection is only 
coming from those with VL and PKDL. Halving the chance of developing symptoms (2) also 
has a considerable impact on transmission, especially if only symptomatic individuals are 
infective after which elimination takes about 10 years. However, if most infection pressure 
arises from asymptomatic individuals, the impact of halving the development of symptoms 
will lead to achieving the elimination target only after about 19 years, when used as a stand-
alone tool. A 50% reduction in the development of PKDL (3), after which not 5% (default) 
but only 2.5% of past VL cases develop PKDL, has the smallest impact on transmission. As 
expected with this characteristic, the relatively larger impact is seen when only those with VL 
and PKDL contribute to transmission, and thus when PKDL plays a more prominent role in 
the transmission dynamics. Of all vaccine characteristics, the development of immunity that 
protects against infection (as seen in late recovered cases) of the population causes the most 
rapid decrease in incidence (4), since the pool of susceptible individuals is completely 
removed at once (with the assumption of 100% coverage as used in the model). We 
additionally explored the effect of vaccinating half the population and repeating this yearly 
for 5 years in a row (5 x 50%), showing that regular vaccinations are required to sustain the 
impact and move towards the elimination target. 
 
The minimum vaccine effect required for each vaccine characteristic to achieve the VL 
elimination target incidence of 1/10,000/year within 10 years of starting the intervention is 
presented in Table 2. The vaccine characteristics that impact the development of VL and 
PKDL (2 and 3) obviously have a bigger impact in the model in which only VL and PKDL 
contribute to transmission.  
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Fig 2. The impact of different vaccine characteristics on VL incidence using model variants with and 
without asymptomatics contributing to transmission in a setting with a pre-control endemicity of 
5/10,000/year. Vaccine characteristics are in place continuously from year 0 onwards, unless for vaccine 
characteristic 4, which is administered once (1 x 100%), or yearly for five years in a row (5 x 50%). The 
different vaccine characteristics that are also explained in Table 1 and illustrated in Fig 1, are; 1a) early 
and late asymptomatic individuals become half as infectious, 1b) all infection states become half as 
infectious, 2) vaccinated individuals are 50% less likely to develop symptoms, 3) vaccinated individuals 
are 50% less likely to develop PKDL, and 4) vaccinated individuals become immediately immune. The 
black dashed line represents the WHO elimination target of 1/10,000/year. The oscillations in VL 
incidence are a result of seasonality in the sand fly density. 
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Table 2. Minimum required effect of the vaccine characteristics to reach a VL elimination target 
incidence of 1/10,000/year within 10 years’ time after starting the intervention, when vaccinating 
100% of the population in a setting with a 5/10,000/year pre-control incidence. 
 Model variant 
Vaccine characteristic 
Only VL and PKDL 
contribute to 
transmission 
Asymptomatics are 
main contributors 
to transmission 
1a) required reduction in infectivity of asymptomatic 
individuals 
N/A 35% 
1b) required reduction in infectivity of all infected 
individuals 
60% 37% 
2) required reduction in the development of symptoms 56% 68%  
3) required amount of time to reach the elimination target 
when preventing the development of PKDL completely 
11 years >20 years 
4) required minimum number of rounds when vaccinating 
50% of the susceptible individuals yearly with 100% 
vaccine efficacy 
14 rounds 5 rounds 
 
Vaccine characteristic 3, after which vaccinated individuals are less likely to develop PKDL, 
displayed the least impact when used as a stand-alone tool. Fig 3 shows the impact on VL 
incidence of a decrease in the development of PKDL of 50% and 100%, combined with the 
current interventions for a setting with a pre-control endemicity level of 5/10,000/year. The 
red line represents the default scenario in which the current interventions (active case 
detection and vector control) are in place during the WHO attack phase (year 0—5) and the 
WHO consolidation phase (year 5—10), without the presence of a vaccine. After halting all 
interventions at year 10, the situation will slowly return to the pre-control equilibrium of 
5/10,000/year. In the two scenarios with the PKDL vaccine (green and blue lines) a new, 
much lower, equilibrium will be reached after regular interventions are halted. For the 
vaccine with a 50% efficacy (50% decrease in PKDL development of vaccinated VL cases) 
the target of 1/10,000/year will be reached as simulated by the model in which only VL and 
PKDL contribute to transmission. When assuming an effect of 100% protection from 
developing PKDL, this model suggests that using only vaccine 3 could keep the incidence 
below 1/10,000/year, after all regular interventions have brought incidence down and are 
halted. However, in settings with a higher pre-control endemicity of 10/10,000/year, only the 
 . CC-BY 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted May 8, 2020. .https://doi.org/10.1101/2020.05.05.20090480doi: medRxiv preprint 
 
 
11 
vaccine with 100% protection against development of PKDL will lead to the elimination 
target of VL after 15-20 years depending on the start year of the PKDL vaccine.  
 
 
 
 
Fig 3. Strategies of combining vaccine effect 3 with the WHO attack and consolidation phase for a 
setting with a pre-control endemicity level of 5/10,000/year. Top panels: vaccine effect with 100% 
protection against the development of PKDL, bottom panels: vaccine effect with 50% protection 
against the development of PKDL. The default strategy is visualized with the red line (top and bottom 
row identical), in which 5 years of attack phase are followed by 5 years of consolidation phase, after which 
interventions are halted in year 10. For the green line, the PKDL vaccine is introduced during the 
consolidation phase (year 5), which continues after the consolidation phase has ended at year 10. For the 
blue line, the PKDL vaccine is already introduced at the start of the attack phase (year 0), continues during 
the consolidation phase and is continued when regular interventions are halted in year 10. Left figures 
show the simulations for the model variant where solely symptomatic individuals contribute to 
transmission, whereas for the right figures asymptomatic individuals constitute the main reservoir of 
infection. The black dashed line represents the WHO VL incidence target of 1/10,000/year. The 
oscillations in VL incidence are a result of seasonality in the sand fly density. 
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Discussion 
In this study, we present for the first time the potential impact of VL vaccines on 
transmission dynamics and population incidence on the Indian subcontinent (ISC). This 
impact looks very promising. We found that all simulated vaccine characteristics show 
potential in reducing population VL incidence, particularly those that reduce the infected 
individual’s infectiousness or reduce the chance of developing symptoms once infected. For 
these vaccines, an approximate 60% vaccine efficacy would lead to achieving the ISC 
elimination target (<1 VL case per 10,000 population per year) within 10 years’ time in a 
moderately endemic setting, assuming that the entire population is vaccinated and only VL 
and PKDL cases contribute to transmission. For the model variant in which asymptomatics 
are the main contributors to transmission, much lower vaccine efficacies of around 37% 
would be required when reducing the infectiousness; however, for the required reduction in 
the development of symptoms, a vaccine efficacy of nearly 70% was estimated. The vaccine 
that leads to immunity akin to that of late recovered cases shows the highest impact, but 
individuals would require regular booster vaccines to achieve and sustain the elimination 
target. Vaccinating VL cases to prevent the development of PKDL shows to be a promising 
tool to sustain the elimination target once reached, and prevent recrudescence of infection 
when regular interventions are halted. Those findings are of great importance in providing a 
factual base to the ongoing effort aimed at establishing a TPP for a VL vaccine.  
 
A limitation to our study is the fact that we simulated vaccine characteristics rather 
simplistically by instantaneously altering the transition rates and applying this simultaneously 
to all individuals in the population. Ideally, vaccinated individuals should move to different, 
additional, compartments in the model, where they experience a different history of infection. 
In such a model, vaccinated and unvaccinated individuals would be living beside each other, 
both influencing the transmission dynamics differently, although the outcomes would likely 
only differ quantitatively with ours. Another limitation of our study is that we only present 
the results for a setting with a pre-control endemicity of 5 VL cases per 10,000 population per 
year, which we considered representative for endemic situations where vaccines would be 
most useful. In settings with a lower pre-control endemicity the elimination target would be 
achieved earlier; in settings with a higher pre-control endemicity, the vaccine characteristics 
would require a higher efficacy to achieve the same effect on VL incidence in the same 
amount of time.  
 . CC-BY 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted May 8, 2020. .https://doi.org/10.1101/2020.05.05.20090480doi: medRxiv preprint 
 
 
13 
 
We further decided to simulated the vaccine characteristics separately, while in reality most 
vaccines are expected to possess multiple characteristics. For example lowering the parasite 
load will likely lead to both decreased infectiousness as well as reduced development of 
symptoms, as is also seen in canine VL vaccines [11]. However, by combining them it would 
be less clear to what extent different characteristics would drive the total impact of a vaccine. 
For the vaccine that causes vaccinated individuals to develop transient immunity against 
infection, it is important to note that the impact on VL incidence, as well as the required 
number of booster vaccines, highly depends on the duration of acquired immunity, which was 
assumed to be two years on average in our models similar that what we used in previous 
work [34]. The longer the duration of acquired immunity, the bigger the impact on VL 
incidence and the lower the frequency of required booster vaccines. We also assume that for 
all vaccine characteristics the efficacy is 50%. Even though this is a generalization and in 
reality it is likely different for each characteristic, this approach allows us to compare the 
impact of the different vaccine characteristics.  
A typical aspect of the deterministic model that we use is that all durations of states are 
exponentially distributed, which often does not reflect the actual distributions of durations as 
found in nature. The slow recrudescence of infection between year 10 and 20 is another 
phenomenon of the deterministic model, where prevalences can never become completely 
zero, but in reality the disease will either die out or come back, and if it comes back, most 
likely it will progress somewhat faster. Around the elimination target when numbers of 
infected cases become very low, the role of chance increases and a stochastic individual-
based transmission model (IBM) would be required to analyse the risks of recrudescence or 
the chance of achieving (local) elimination of transmission. 
 
We acknowledge that some of the assumptions chosen for the simulation are not fully 
reflective of the reality of implemented immunization programs. Firstly, our choice of 100% 
coverage certainly is an overestimation of what can be realistically achieved. For example, 
coverage for the 1st dose of measles-containing vaccines was on average 73% in the AFRO 
region, and the human papilloma virus vaccination had an average coverage of 88% when 
pooling regions and income levels [37,38]. However, this assumption allowed us to evaluate 
the maximum impact and to do such an evaluation independently from the constraints of 
delivery strategy. Also, having chosen another coverage level would not alter our outcomes 
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when comparing the impact of the different characteristics. With a lower coverage, the 
durations until elimination would be longer and the minimum required efficacies would be 
higher. Secondly, and in particular at the start of vaccination programs, a catch up campaign 
is usually implemented to quickly reduce the susceptible population, focusing on the 
population that is at highest risk (i.e. for leishmaniasis, children and young adults or migrant 
workers [39]). Such programmatic design considerations are not considered in the current 
model and will need to be investigated with more complex IBMs. Lastly, 5-year protection is 
most likely going to be the minimum requirement to allow for a widespread roll-out in 
routine immunization. Shorter durations requiring a very frequent administration of booster 
doses might prove programmatically and financially unsustainable. Nevertheless, from an 
impact assessment standpoint the results generated with the more conservative assumptions 
of the current model have clear significance for understanding the relative importance of 
different vaccine characteristics. 
 
Vaccines have proven to be vital tools in the control and prevention of diseases [40,41]. This 
study reveals that a VL vaccine strategy could also prove an important tool in the fight 
against this neglected tropical disease. We focussed on the anthroponotic transmission 
dynamics of VL on the Indian subcontinent, but also in the rest of the world VL vaccines are 
likely to surpass their impact at the patient level by reducing the infection pressure, positively 
impacting the estimated 6 million people at risk of VL globally [42].  
 
In conclusion, even though VL vaccines are not yet available for implementation, our results 
strongly support their continued development, given the potentially substantive impact on 
transmission, decreasing incidence at the population level, and sustaining the low incidence 
elimination target on the ISC when other interventions are relaxed.  More details of the 
impact of different vaccines characteristics on the history of infection are awaited to further 
our understanding and modelling of the impact of VL vaccines on VL transmission dynamics 
and disease incidence. 
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